AbbVie | PRE 14A: Preliminary proxy statements relating to merger or acquisition
AbbVie | 8-K: Notes Offering
AbbVie | 8-K: Entered into an Underwriting Agreement
AbbVie | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
AbbVie | 8-K: AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
AbbVie | 8-K: Revolving Credit Agreement
AbbVie | 8-K: Current report
AbbVie | 8-K: Guidance Including the Impact of Acquired IPR&D and Milestones Expense
AbbVie | 8-K: Kevin K. Buckbee Plans to Retire as AbbVie's Controller
AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
AbbVie | 8-K: Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited)
AbbVie | 8-K: Current report
AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
AbbVie | 8-K: AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense
AbbVie | 8-K/A: Poll Results of AbbVie Meeting (Amendment)
AbbVie | 8-K: AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense
AbbVie | DEF 14A: Definitive information statements
AbbVie | DEFA14A: Others
AbbVie | PRE 14A: Preliminary proxy statements relating to merger or acquisition